Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  adenocarcinoma of the colon
Stage/Subtype:  adenocarcinoma of the colon
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 33 for your search:
Start Over
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-130-02, NCI-2013-01786, NCT01605318
Quinacrine Hydrochloride and Capecitabine in Treating Patients with Metastatic or Recurrent Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: GI-078, NCI-2016-00139, NCT01844076
Guadecitabine and Irinotecan Hydrochloride or Regorafenib or TAS-102 Alone in Treating Patients with Previously Treated Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NA_00085870, J1369, NCI-2013-02005, CIR00004735, CIR00013885, CIR0002117, NA_00085870, NCT01896856
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204, NCI-2015-00040, NCT02327078
Nintedanib and Capecitabine in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 265514, NCI-2015-00223, NCT02393755
Irinotecan Hydrochloride and Cetuximab with or without Ramucirumab in Treating Patients with Advanced Colorectal Cancer with Progressive Disease after Treatment with Bevacizumab-Containing Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E7208, NCI-2011-02018, CDR0000666736, ECOG-E7208, NCT01079780
Combination Chemotherapy with or without Regorafenib in Treating Patients with Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1029, NCI-2013-00954, 10-2176, NCT01298570
Combination Chemotherapy with or without Panitumumab in Treating Patients with Colorectal Cancer with Liver Metastases Previously Treated with Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-137, NCI-2011-00375, NCT01312857
Combination Chemotherapy, Bevacizumab, and Cholecalciferol in Treating Patients with Previously Untreated Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-436, NCI-2012-00662, NCT01516216
Gemcitabine Hydrochloride and Docetaxel in Treating Patients with Relapsed or Refractory Colorectal Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: J1214, NCI-2012-01337, CIR00009096, NA_00069666, NA_00069666 / CIR00009096, NCI-2013-01567, NCT01639131
Ziv-Aflibercept and Combination Chemotherapy in Treating Patients with Previously Untreated Colorectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 11182, NCI-2012-01167, 2012C0055, NCT01652196
Panitumumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Combination Chemotherapy and Bevacizumab
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OSU-11131, NCI-2013-00432, 2012C0033, NCT01814501
Pembrolizumab in Treating Patients with Metastatic or Locally Advanced Microsatellite Unstable Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1365, NCI-2013-02436, CIR00001187, MK-3475-016, NA_00085756, NA_00085756 / CIR00007001, NCT01876511
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IMMU 130-03, NCI-2014-01921, NCT01915472
Regorafenib in Treating Patients with Newly Diagnosed Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-211, NCI-2014-00002, NCT02023333
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-21-02, NCI-2014-00908, NCT02096354
Genetic Testing in Determining Irinotecan Hydrochloride Dose in Patients with Metastatic Colorectal Cancer Receiving FOLFIRI and Bevacizumab
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1317, NCI-2014-01408, 13-3413, NCT02138617
Lower or Standard Dose Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RU021407I, NCI-2015-00011, Mod14-008756-03, NCT02368886
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HCRN GI14-186, NCI-2015-01466, NCT02375672
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13050, NCI-2015-01790, NCT02425683
Regorafenib in Metastatic Colorectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 70 and over
Trial IDs: 55555, NCI-2016-00641, NCT02466009
Biweekly Intraperitoneal Oxaliplatin with Systemic Capecitabine and Bevacizumab for Patients with Peritoneal Carcinomatosis from Appendiceal or Colorectal Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-0136 / 201107017, NCI-2011-01043, 10-0136, NCT01061515
Combination Chemotherapy in Treating Patients With Previously Untreated Locally Advanced or Metastatic Gastrointestinal Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0033, NCI-2012-00585, 12-0033-AM010, NCT01643499
Start Over